Cargando…

Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2(+ )and decreased levels of IL23R(+ )CD4(+ )T - Lymphocytes in multiple sclerosis

BACKGROUND: There are a lack of biomarkers which can be used to predict clinical outcomes for multiple sclerosis (MS) patients receiving interferon beta (IFN-β). Thus the objective of this study was to characterize changes in CD4+ T-lymphocyte expression in an unbiased manner following initiation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kress-Bennett, Jennifer M, Ehrlich, Garth D, Bruno, Ashley, Post, J Christopher, Hu, Fen Z, Scott, Thomas F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292517/
https://www.ncbi.nlm.nih.gov/pubmed/22182694
http://dx.doi.org/10.1186/1471-2377-11-155
_version_ 1782225289716170752
author Kress-Bennett, Jennifer M
Ehrlich, Garth D
Bruno, Ashley
Post, J Christopher
Hu, Fen Z
Scott, Thomas F
author_facet Kress-Bennett, Jennifer M
Ehrlich, Garth D
Bruno, Ashley
Post, J Christopher
Hu, Fen Z
Scott, Thomas F
author_sort Kress-Bennett, Jennifer M
collection PubMed
description BACKGROUND: There are a lack of biomarkers which can be used to predict clinical outcomes for multiple sclerosis (MS) patients receiving interferon beta (IFN-β). Thus the objective of this study was to characterize changes in CD4+ T-lymphocyte expression in an unbiased manner following initiation of intramuscular (IM) IFN-β-1a treatment, and then to verify those findings using marker-specific assays. METHODS: Peripheral blood specimens were collected from twenty MS patients before and after treatment with intramuscular (IM) IFN-β-1a and were used for isolation of mononuclear cells (PBMCs). mRNA expression patterns of negatively-selected CD4+ T-cells from the PBMCs were analyzed using microarray gene expression technology. IL-12 and IL-23 receptor levels on PBMC-derived CD4+ T-cells were analyzed by flow cytometry. The phosphorylation status of Stat4 was measured by performing densitometry on western blots. RESULTS: Microarray analyses demonstrated that mRNA expression of the IL-12Rβ2 gene was uniformly up-regulated in response to IFN-β-1a treatment and was associated with an increased number of IL-12Rβ2(+ )CD4(+ )T-cells by flow cytometry in 4 of 6 patients. This finding was substantiated by demonstrating that Stat4 phosphorylation, a transcription factor for IL-12, was increased after treatment. Conversely, the number of IL-23R(+ )CD4(+ )T-cells was decreased following treatment. CONCLUSIONS: The IL-12 receptor shares a common subunit, the IL-12Rβ2, with the IL-23 receptor. Both of these receptors have a probable role in regulating IL-17 and TH-17 cells, important mediators of inflammation in multiple sclerosis (MS). Thus, the changes in the numbers of CD4(+ )T-cells expressing these receptors in response to IFN-β-1a treatment may point to an important mechanism of action for this drug, but further large scale studies are needed to confirm these preliminary observations.
format Online
Article
Text
id pubmed-3292517
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32925172012-03-03 Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2(+ )and decreased levels of IL23R(+ )CD4(+ )T - Lymphocytes in multiple sclerosis Kress-Bennett, Jennifer M Ehrlich, Garth D Bruno, Ashley Post, J Christopher Hu, Fen Z Scott, Thomas F BMC Neurol Research Article BACKGROUND: There are a lack of biomarkers which can be used to predict clinical outcomes for multiple sclerosis (MS) patients receiving interferon beta (IFN-β). Thus the objective of this study was to characterize changes in CD4+ T-lymphocyte expression in an unbiased manner following initiation of intramuscular (IM) IFN-β-1a treatment, and then to verify those findings using marker-specific assays. METHODS: Peripheral blood specimens were collected from twenty MS patients before and after treatment with intramuscular (IM) IFN-β-1a and were used for isolation of mononuclear cells (PBMCs). mRNA expression patterns of negatively-selected CD4+ T-cells from the PBMCs were analyzed using microarray gene expression technology. IL-12 and IL-23 receptor levels on PBMC-derived CD4+ T-cells were analyzed by flow cytometry. The phosphorylation status of Stat4 was measured by performing densitometry on western blots. RESULTS: Microarray analyses demonstrated that mRNA expression of the IL-12Rβ2 gene was uniformly up-regulated in response to IFN-β-1a treatment and was associated with an increased number of IL-12Rβ2(+ )CD4(+ )T-cells by flow cytometry in 4 of 6 patients. This finding was substantiated by demonstrating that Stat4 phosphorylation, a transcription factor for IL-12, was increased after treatment. Conversely, the number of IL-23R(+ )CD4(+ )T-cells was decreased following treatment. CONCLUSIONS: The IL-12 receptor shares a common subunit, the IL-12Rβ2, with the IL-23 receptor. Both of these receptors have a probable role in regulating IL-17 and TH-17 cells, important mediators of inflammation in multiple sclerosis (MS). Thus, the changes in the numbers of CD4(+ )T-cells expressing these receptors in response to IFN-β-1a treatment may point to an important mechanism of action for this drug, but further large scale studies are needed to confirm these preliminary observations. BioMed Central 2011-12-19 /pmc/articles/PMC3292517/ /pubmed/22182694 http://dx.doi.org/10.1186/1471-2377-11-155 Text en Copyright ©2011 Kress-Bennett et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kress-Bennett, Jennifer M
Ehrlich, Garth D
Bruno, Ashley
Post, J Christopher
Hu, Fen Z
Scott, Thomas F
Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2(+ )and decreased levels of IL23R(+ )CD4(+ )T - Lymphocytes in multiple sclerosis
title Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2(+ )and decreased levels of IL23R(+ )CD4(+ )T - Lymphocytes in multiple sclerosis
title_full Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2(+ )and decreased levels of IL23R(+ )CD4(+ )T - Lymphocytes in multiple sclerosis
title_fullStr Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2(+ )and decreased levels of IL23R(+ )CD4(+ )T - Lymphocytes in multiple sclerosis
title_full_unstemmed Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2(+ )and decreased levels of IL23R(+ )CD4(+ )T - Lymphocytes in multiple sclerosis
title_short Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2(+ )and decreased levels of IL23R(+ )CD4(+ )T - Lymphocytes in multiple sclerosis
title_sort preliminary study: treatment with intramuscular interferon beta-1a results in increased levels of il-12rβ2(+ )and decreased levels of il23r(+ )cd4(+ )t - lymphocytes in multiple sclerosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292517/
https://www.ncbi.nlm.nih.gov/pubmed/22182694
http://dx.doi.org/10.1186/1471-2377-11-155
work_keys_str_mv AT kressbennettjenniferm preliminarystudytreatmentwithintramuscularinterferonbeta1aresultsinincreasedlevelsofil12rb2anddecreasedlevelsofil23rcd4tlymphocytesinmultiplesclerosis
AT ehrlichgarthd preliminarystudytreatmentwithintramuscularinterferonbeta1aresultsinincreasedlevelsofil12rb2anddecreasedlevelsofil23rcd4tlymphocytesinmultiplesclerosis
AT brunoashley preliminarystudytreatmentwithintramuscularinterferonbeta1aresultsinincreasedlevelsofil12rb2anddecreasedlevelsofil23rcd4tlymphocytesinmultiplesclerosis
AT postjchristopher preliminarystudytreatmentwithintramuscularinterferonbeta1aresultsinincreasedlevelsofil12rb2anddecreasedlevelsofil23rcd4tlymphocytesinmultiplesclerosis
AT hufenz preliminarystudytreatmentwithintramuscularinterferonbeta1aresultsinincreasedlevelsofil12rb2anddecreasedlevelsofil23rcd4tlymphocytesinmultiplesclerosis
AT scottthomasf preliminarystudytreatmentwithintramuscularinterferonbeta1aresultsinincreasedlevelsofil12rb2anddecreasedlevelsofil23rcd4tlymphocytesinmultiplesclerosis